Online inquiry

IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8461MR)

This product GTTS-WQ8461MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8461MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3936MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ9169MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ548MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 4D5-8
GTTS-WQ11609MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGD-006
GTTS-WQ13812MR IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-10987
GTTS-WQ11717MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ9200MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ9773MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JS001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW